Drug Trial Radar · NCT02970292
Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
Last checked: Nov 20, 2026Latest source record: Jun 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
396
Actual
Start
Oct 26, 2016
Primary completion
May 28, 2019
Study completion Jun 25, 2019
Sponsor
- Lead sponsor
- ACADIA Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 22, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of schizophrenia
Conditions
- Schizophrenia
Interventions
PimavanserinDrug
Pimavanserin 34 mg, 20 mg, or 10 mg , taken as two tablets once daily by mouth
PlaceboDrug
Placebo, taken as two tablets, once daily by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total ScoreTime frame: From baseline to Week 6
Locations
105 sites in 10 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Little Rock, Arkansas
Site not named
Rogers, Arkansas
Site not named
Bellflower, California
Site not named
Cerritos, California
Site not named
Culver City, California
Site not named
Lemon Grove, California
Site not named
Long Beach, California
Site not named
San Diego, California
Site not named
San Diego, California
Site not named
Santa Ana, California
Site not named
Torrance, California
Site not named
Boca Raton, Florida
Site not named
Lauderhill, Florida
Site not named
Miami, Florida
Site not named
Atlanta, Georgia
Site not named
Atlanta, Georgia
Site not named
Chicago, Illinois
Site not named
Chicago, Illinois
Site not named
Hoffman Estates, Illinois
Site not named
Lake Charles, Louisiana
Site not named
Catonsville, Maryland
Site not named
Ann Arbor, Michigan
Site not named
Las Vegas, Nevada
Site not named
Berlin, New Jersey
Site not named
Cedarhurst, New York
Site not named
Jamaica, New York
Site not named
Rochester, New York
Site not named
Charlotte, North Carolina
Site not named
Dayton, Ohio
Site not named
Charleston, South Carolina
Site not named
Richardson, Texas
Site not named
Salt Lake City, Utah
Site not named
Burgas, Bulgaria
Site not named
Pazardzhik, Bulgaria
Site not named
Plovdiv, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Sofia, Bulgaria
Showing 40 of 105 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.